Compare · ARGX vs ARMP
ARGX vs ARMP
Side-by-side comparison of argenx SE (ARGX) and Armata Pharmaceuticals Inc. (ARMP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ARMP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 457.1x ARMP ($114.9M).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 4 for ARMP).
- ARGX has more recent analyst coverage (25 ratings vs 0 for ARMP).
- Company
- argenx SE
- Armata Pharmaceuticals Inc.
- Price
- $819.19-3.28%
- $3.35+8.41%
- Market cap
- $52.52B
- $114.9M
- 1M return
- -17.73%
- -
- 1Y return
- -2.77%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest ARMP
- Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
- Armata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
- Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
- Armata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
- Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
- SEC Form 10-Q filed by Armata Pharmaceuticals Inc.
- Armata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits